Apidra is a new insulin analogue for the treatment of vascular complications in diabetes

Abstract

To achieve glycemic targets, as the main preventive measure for vascular complications, patients with type 1 diabetes need lifelong administration of insulin in a regimen that allows them to have euglycemia both before and after eating. For this, optimal insulin therapy regimens have been created, which necessarily include short-acting insulin (with the main meal) and medium or long-acting insulin as basal. This mode of administration allows you to maximize bring the daily fluctuations of insulin administered to the natural rhythm of insulin secretion in healthy people.